The Latest Cardiac and Vascular News
Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development BOSTON, April 5, 2022 /PRNewswire/ — Valo Health, LLC (“Valo”), announced today the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular […]
Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and […]
NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This financing will be used to scale TARA’s cardiac tissue engineering […]
NEW YORK, Sept. 27, 2018 /PRNewswire/ — TARA Biosystems Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications, announced today the launch of Cardiotype.Fo, the best-in-class in vitrosystem for assessment of cardiac contractility. Contractility of heart muscle tissue is a […]
SANTA CLARA, Calif., Sept. 25, 2018 /PRNewswire/ — Based on its recent analysis of the North American heart-on-a-chip market, Frost & Sullivan recognizes TARA Biosystems with the 2018 North American Technology Innovation Award for its trailblazing Biowire™ II heart-on-a-chip platform. This solution produces mature, […]
NEW YORK, May 30, 2018 /PRNewswire/ — TARA Biosystems Inc., a company offering physiologically relevant, human “heart-on-a-chip” tissue-models for drug discovery and development applications, is proud to announce that TARA CEO Dr. Misti Ushio has been recognized by Fast Company as one of the Top 100 […]
